Group A received an in situ tissue-engineered graft containing 54 38 CD34 + cells/mL along with 54 38 CD44 + , CD90 + , and CD105 + cells/mL together with rhBMP-2 in an absorbable collagen sponge ( 1 mg/cm of defect ) and crushed cancellous allogeneic bone .